PURPOSE: Allogeneic hematopoietic cell transplantation (HCT) is the only potentially curative therapy for myelodysplastic syndromes (MDS), although it is infrequently offered to older patients. The relative benefits of HCT over non-HCT therapy in older patients with higher-risk MDS have not been defined. METHODS: We conducted a multicenter biologic assignment trial comparing reduced-intensity HCT to hypomethylating therapy or best supportive care in subjects 50-75 years of age with intermediate-2 or high-risk de novo MDS. The primary outcome was overall survival probability at 3 years. Between January 2014 and November 2018, we enrolled 384 subjects at 34 centers. Subjects were assigned to the Donor or No-Donor arms according to the availability of a matched donor within 90 days of study registration. RESULTS: The median follow-up time for surviving subjects was 34.2 months (range: 2.3-38 months) in the Donor arm and 26.9 months (range: 2.4-37.2 months) in the No-Donor arm. In an intention-to-treat analysis, the adjusted overall survival rate at 3 years in the Donor arm was 47.9% (95% CI, 41.3 to 54.1) compared with 26.6% (95% CI, 18.4 to 35.6) in the No-Donor arm (P = .0001) with an absolute difference of 21.3% (95% CI, 10.2 to 31.8). Leukemia-free survival at 3 years was greater in the Donor arm (35.8%; 95% CI, 29.8 to 41.8) compared with the No-Donor arm (20.6%; 95% CI, 13.3 to 29.1; P = .003). The survival benefit was seen across all subgroups examined. CONCLUSION: We observed a significant survival advantage in older subjects with higher-risk MDS who have a matched donor identified and underwent reduced-intensity HCT, when compared with those without a donor. HCT should be included as an integral part of MDS management plans in fit older adults with higher-risk MDS.
PURPOSE: Allogeneic hematopoietic cell transplantation (HCT) is the only potentially curative therapy for myelodysplastic syndromes (MDS), although it is infrequently offered to older patients. The relative benefits of HCT over non-HCT therapy in older patients with higher-risk MDS have not been defined. METHODS: We conducted a multicenter biologic assignment trial comparing reduced-intensity HCT to hypomethylating therapy or best supportive care in subjects 50-75 years of age with intermediate-2 or high-risk de novo MDS. The primary outcome was overall survival probability at 3 years. Between January 2014 and November 2018, we enrolled 384 subjects at 34 centers. Subjects were assigned to the Donor or No-Donor arms according to the availability of a matched donor within 90 days of study registration. RESULTS: The median follow-up time for surviving subjects was 34.2 months (range: 2.3-38 months) in the Donor arm and 26.9 months (range: 2.4-37.2 months) in the No-Donor arm. In an intention-to-treat analysis, the adjusted overall survival rate at 3 years in the Donor arm was 47.9% (95% CI, 41.3 to 54.1) compared with 26.6% (95% CI, 18.4 to 35.6) in the No-Donor arm (P = .0001) with an absolute difference of 21.3% (95% CI, 10.2 to 31.8). Leukemia-free survival at 3 years was greater in the Donor arm (35.8%; 95% CI, 29.8 to 41.8) compared with the No-Donor arm (20.6%; 95% CI, 13.3 to 29.1; P = .003). The survival benefit was seen across all subgroups examined. CONCLUSION: We observed a significant survival advantage in older subjects with higher-risk MDS who have a matched donor identified and underwent reduced-intensity HCT, when compared with those without a donor. HCT should be included as an integral part of MDS management plans in fit older adults with higher-risk MDS.
Authors: R P McQuellon; G B Russell; D F Cella; B L Craven; M Brady; A Bonomi; D D Hurd Journal: Bone Marrow Transplant Date: 1997-02 Impact factor: 5.483
Authors: P Greenberg; C Cox; M M LeBeau; P Fenaux; P Morel; G Sanz; M Sanz; T Vallespi; T Hamblin; D Oscier; K Ohyashiki; K Toyama; C Aul; G Mufti; J Bennett Journal: Blood Date: 1997-03-15 Impact factor: 22.113
Authors: W G Woods; S Neudorf; S Gold; J Sanders; J D Buckley; D R Barnard; K Dusenbery; J DeSwarte; D C Arthur; B J Lange; N L Kobrinsky Journal: Blood Date: 2001-01-01 Impact factor: 22.113
Authors: Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman Journal: Lancet Oncol Date: 2009-02-21 Impact factor: 41.316
Authors: Mikkael A Sekeres; W Marieke Schoonen; Hagop Kantarjian; Alan List; Jon Fryzek; Ronald Paquette; Jaroslaw P Maciejewski Journal: J Natl Cancer Inst Date: 2008-10-28 Impact factor: 13.506
Authors: Ehab Atallah; Brent Logan; Min Chen; Corey Cutler; Joachim Deeg; Meagan Jacoby; Richard Champlin; Taiga Nishihori; Dennis Confer; James Gajewski; Stephanie Farnia; Peter Greenberg; Erica Warlick; Daniel Weisdorf; Wael Saber; Mary M Horowitz; J Douglas Rizzo Journal: JAMA Oncol Date: 2020-04-01 Impact factor: 31.777
Authors: Wael Saber; Jennifer Le Rademacher; Mikkael Sekeres; Brent Logan; Moira Lewis; Adam Mendizabal; Eric Leifer; Frederick R Appelbaum; Mary M Horowitz; Ryotaro Nakamura; Corey S Cutler Journal: Biol Blood Marrow Transplant Date: 2014-06-24 Impact factor: 5.742
Authors: Mikkael A Sekeres; Megan Othus; Alan F List; Olatoyosi Odenike; Richard M Stone; Steven D Gore; Mark R Litzow; Rena Buckstein; Min Fang; Diane Roulston; Clara D Bloomfield; Anna Moseley; Aziz Nazha; Yanming Zhang; Mario R Velasco; Rakesh Gaur; Ehab Atallah; Eyal C Attar; Elina K Cook; Alyssa H Cull; Michael J Rauh; Frederick R Appelbaum; Harry P Erba Journal: J Clin Oncol Date: 2017-05-09 Impact factor: 50.717
Authors: C Lindholm; E Olofsson; M Creignou; L Nilsson; H Gravdahl Garelius; J Cammenga; P Ljungman; E Ejerblad; M Tobiasson Journal: Bone Marrow Transplant Date: 2022-02-02 Impact factor: 5.483